The article discusses the therapeutic options for treating the 2019 novel coronavirus (2019-nCoV, now known as COVID-19). As of February 10, 2020, the virus had spread to 25 countries across 4 continents, with over 40,000 confirmed cases and an estimated mortality rate of ~2%. No specific drug or vaccine has been approved for treating human coronaviruses. The authors focus on repurposing existing antiviral agents, including nucleoside analogues (favipiravir and ribavirin), experimental nucleoside analogues (remdesivir and galidesvir), protease inhibitors (disulfiram, lopinavir, and ritonavir), and host-targeted agents (pegylated interferon alfa-2a and -2b, chloroquine, and nitazoxanide). These agents have shown potential against related coronaviruses such as SARS and MERS. Phase III trials of remdesivir have been initiated, and other trials are being established to test various treatment options. The authors emphasize the urgent need for broad-spectrum antiviral agents to combat coronaviruses.The article discusses the therapeutic options for treating the 2019 novel coronavirus (2019-nCoV, now known as COVID-19). As of February 10, 2020, the virus had spread to 25 countries across 4 continents, with over 40,000 confirmed cases and an estimated mortality rate of ~2%. No specific drug or vaccine has been approved for treating human coronaviruses. The authors focus on repurposing existing antiviral agents, including nucleoside analogues (favipiravir and ribavirin), experimental nucleoside analogues (remdesivir and galidesvir), protease inhibitors (disulfiram, lopinavir, and ritonavir), and host-targeted agents (pegylated interferon alfa-2a and -2b, chloroquine, and nitazoxanide). These agents have shown potential against related coronaviruses such as SARS and MERS. Phase III trials of remdesivir have been initiated, and other trials are being established to test various treatment options. The authors emphasize the urgent need for broad-spectrum antiviral agents to combat coronaviruses.